45 results about "Excess weight" patented technology

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

The present invention relates to compositions and methods for use in the prevention or treatment of excess weight in a mammal. The compositions comprise oxyntomodulin which is shown to reduce food intake and / or increase energy expenditure.

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

A food product, suitable for a controllled carbohydrate diet comprises identifiable pieces of cereal-like core held together with a binding agent, with the product being 30% or less in digestible carbohydrate. The product may be consumed as part of a weight loss or maintenance program, or as nutritional support in any case where escessive blood sugar is to be avoided, such as in subjects suffering from excess weight or obesity, hyperglycemia, insulin resistance and types I and I diabetes.

The invention discloses a constrained damping plate optimization design method based on a bidirectional evolutionary optimization algorithm and belongs to the technical field of optimal structural designing. The method includes the steps of establishing a finite element model of constrained damping plate; establishing a topological optimization model; setting parameters of the bidirectional evolutionary optimization algorithm; calculating sensitivities of constrained damping plate structural units; gradually deleting low-efficiency ones of the constrained damping plate structural units by the bidirectional evolutionary optimization algorithm, and restoring high-sensitivity deleted ones of the constrained damping plate structural units; stopping iteration when constraint conditions are met, and outputting an optimal layout of constrained damping material. The method has the advantages that a modal loss factor of the constrained damping plate is maximized under certain usage of the constrained damping material, and the constrained damping plate structure effectively damps on the premise of no excess weight being added.

Gastric stimulation systems and methods are provided for treating a patient, particularly by modifying behavior of the patient leading to excess weight loss. In some embodiments, such weight loss is achieved with a combination approach which includes two or more of the following: acute screening of the potential patients, gastric stimulation, induction of symptoms or specific behaviors and integration of patient management data into the treatment plan. Gastric stimulation is provided to portions of the gastrointestinal tract, particularly the stomach, with the use of at least one electrode. A variety of gastric stimulation systems may be used, including stimulators that are endoscopically placed, laparoscopically placed or placed by modified or combination methods.

Methods and devices create an intestinal braking effect, are non-invasive or minimally invasive, and may be reversible. These methods and devices are accomplished via stabilized implantable systems, and ingestible pills. In one embodiment, the implantable system comprises a device delivering a therapeutic substance to a target location within the gastrointestinal tract of a patient in order to initiate an intestinal braking effect which would promote sensations of satiety and stimulate excess weight loss for the patient.

As weight restrictions become more stringent, air, train and bus passengers are being faced with the increasing cost of excess baggage weight. The proposed system makes use of transducers built into the bag or its handle both for weight monitoring and for theft protection. In the weight monitoring mode, designed for use during packing, an excess weight alarm is triggered when a preset maximum value is exceeded. In the theft protection mode, the transducer signal triggers an alarm as soon as the bag is picked up, thus giving early warning of possible theft. In this mode the signal is preferably transmitted to an external device such as a cellular phone for remote audible and / or visible indication. Because the circuits are switched on only when the suitcase or bag is picked up, battery life is practically equal to shelf life, hence ensuring high system availability.

Use of at least one strain of a microorganism and / or a metabolite thereof in the manufacture of a support for administration to a subject for modulating satiety signalling, wherein the support is a pharmaceutically acceptable support or a food product. Suitably, the at least one strain of a microorganism and / or a metabolite thereof may be administered to the subject for the treatment and / or prevention of excess weight and / or a disease caused by excess weight. Likewise, the at least one strain of a microorganism and / or a metabolite thereof is administered to the subject for the treatment and / or prevention of obesity and / or a caused by obesity. Preferably, the microorganism is a probiotic microorganism. Suitably the microorganism may be a lactic acid bacterium. Li one embodiment the microorganism is a strain of Lactobacillus spp. and / or Bifidobacterium spp., for example a strain of Lactobacillus acidophilus, L. curvatus, L. salivarius and / or B. lactis.

A strong, light weight walking aid with optional seat that can be used to assist a person in walking and resting on the walking aid. The walking aid collapses so that it can be stored in a small space and the handle can be removed and reattached to make it even smaller. The walking aid is constructed of a double tube aluminum frame to make it strong without adding excess weight. It is provided with a padded, sure-grip handle and can be provided with braking mechanisms on some or all of the wheels.

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Provided are methods for selecting melanocortin receptor-specific compounds for attenuating food intake and for treatment of specific disease conditions, including treatment of obesity and related energy homeostasis or feeding disorders characterized by excess weight gain, without inducing a sexual response, and methods for selecting compounds for treatment of sexual dysfunction. Further provided are pharmaceutical preparations defined by such methods, and methods and preparations for attenuating food intake and treatment of said conditions.

Use of at least one strain of a microorganism and / or a metabolite thereof in the manufacture of a support for administration to a subject for modulating satiety signalling, wherein the support is a pharmaceutically acceptable support or a food product. Suitably, the at least one strain of a microorganism and / or a metabolite thereof may be administered to the subject for the treatment and / or prevention of excess weight and / or a disease caused by excess weight. Likewise, the at least one strain of a microorganism and / or a metabolite thereof is administered to the subject for the treatment and / or prevention of obesity and / or a caused by obesity. Preferably, the microorganism is a probiotic microorganism. Suitably the microorganism may be a lactic acid bacterium. Li one embodiment the microorganism is a strain of Lactobacillus spp. and / or Bifidobacterium spp., for example a strain of Lactobacillus acidophilus, L. curvatus, L. salivarius and / or B. lactis.

Methods and devices create an intestinal braking effect, are non-invasive or minimally invasive, and may be reversible. These methods and devices are accomplished via stabilized implantable systems, and ingestible pills. In one embodiment, the implantable system comprises a device delivering a therapeutic substance to a target location within the gastrointestinal tract of a patient in order to initiate an intestinal braking effect which would promote sensations of satiety and stimulate excess weight loss for the patient.

The application discloses a road surface maintenance early warning method and device; the method of one specific embodiment comprises the following steps: obtaining maintenance data of each sub road section of an object road, wherein the maintenance data comprises the start time of each maintenance work of said sub road sections; obtaining vehicle traffic data passing each sub road section from the start time of the previous maintenance work, wherein the vehicle traffic data comprises vehicle traffic flow, and load capacity and excess weight of each vehicle; determining the traffic flow integral amount of said sub road section according to the vehicle traffic flow of each sub road section and the load capacity and excess weight of each vehicle passing the sub road section; forming early warning information of the road surface maintenance work of each sub road section in the object road according to the traffic flow integral amount of each sub road section of the object road. The method and device can realize dynamic early warning of the road surface maintenance work.

The present invention provides a method of promoting weight loss, or treating or preventing a body disorder related to excess weight, in a subject. The method comprises administering to the subject an effective amount of a creatine uptake inhibitor. Administration of the creatine uptake inhibitor is intracranial or directed to the hypothalamus. The invention further provides a method of screening for a novel compound that inhibits creatine uptake in the hypothalamus.

An inflatable game ball containing a noise suppression device and a method for inflating the game ball are described. More particularly, a free standing, noise suppression disk is fit snuggly within a central area of the hollow internal cavity formed by the bladder of the game ball. The diameter of the noise suppression disk is slightly larger than the diameter of the hollow internal cavity of the ball, while the thickness of the disk is sufficient to provide necessary rigidity to the game ball noise suppressor without adding excess weight to the ball. An exact amount of SF6 is pre-filled in the balls, when combined with subsequent air, is determined to create the ultimate SF6 to air ratio range at various altitude levels. Subsequently, the balls are only partially inflated at the time of manufacture with the SF6 gas, and no air.

The inventive method for automatically analysing a cellular sample consists (a) in colouring the cell nucleuses of a sample, (b) inobtaining at least one digital picture of the sample, and (c) in digitally analysing said image and is characterised in that the cell nucleus colouring stage (2) is embodied in the form of a DNA-non-specific colouring. In order to use the inventive method, said invention also relates to a method for selecting a culture medium, a method for measuring substance toxicity and to a method for measuring the cytopathological characteristics of a virus. A method for selecting pharmacological substances for treating excess weight and obesity diseases and a method for selecting substances for treating osteoporosis are also disclosed.

A combination product includes as active substances, at least an inhibitor of the HMG-CoA-reductase enzyme and citrulline, or a bioequivalent compound thereof, for treating excess weight or obesity and / or the accumulation of body fat. A cosmetic treatment method for improving or slimming the figure and / or for stimulating the loss of excess weight and / or of cellulite and / or for limiting the accumulation thereof, includes the administration of a combination product including as active substances, at least an inhibitor of the HMG-CoA-reductase enzyme or a physiologically acceptable salt thereof, and citrulline, or a bioequivalent compound thereof, or one of theirs analogues, and the renewal of the administration until the expected cosmetic effect is obtained. The combination product such as previously defined for improving or slimming the figure and / or for stimulating the loss of excess weight and / or of cellulite and / or for limiting the accumulation thereof is also described.

The object of the invention are compositions and medical treatment methods with an inheritable, Gram-negative, strictly anaerobic and commensal bacterium of the family Christensenellaceae belonging to an OTU (Operational Taxonomic Unit) characterized by a 16S rRNA sequence SEQ ID NO: 1 or to an OTU characterized by a165 rRNA sequence SEQ ID NO: 2.

The present invention relates to the pharmaceutical field, especially the field of combination and pharmaceutical compositions that comprise a lipase inhibitor and a phytoalexin and pharmaceutically acceptable vehicles or excipients; the present invention also relates to the method for manufacturing compositions containing the combination and the use of said composition in the treatment of conditions of excess weight, obesity and related health problems.

An inflatable game ball containing a noise suppression device and a method for inflating the game ball are described. More particularly, a free standing, noise suppression disk is fit snuggly within a central area of the hollow internal cavity formed by the bladder of the game ball. The diameter of the noise suppression disk is slightly larger than the diameter of the hollow internal cavity of the ball, while the thickness of the disk is sufficient to provide necessary rigidity to the game ball noise suppressor without adding excess weight to the ball. An exact amount of SF6 is pre-filled in the balls, when combined with subsequent air, is determined to create the ultimate SF6 to air ratio range at various altitude levels. Subsequently, the balls are only partially inflated at the time of manufacture with the SF6 gas, and no air.

A nutraceutical composition is provided for the treatment of excess weight and moderate hypercholesterolemia / dysglycemia, comprising: Berberine, Monacolin K, 1-deoxynojirimycin (DNJ).

The invention relates to the use of leptin in the preparation of an ingestible composition for children from nursing infants to adolescents, comprising leptin at a concentration greater than 50 ng / kg, for the prevention of excess weight and / or the complications associated therewith. The invention comprises the use of a fully- or partially-hydrolysed recombinant leptin. Said ingestible composition is a supplement for developmental nutrition, contains between 0.1 and 30 micrograms / litre leptin, provides a daily dose of leptin of more than 25 ng and can take the form of a solid, i.e. a tablet, capsule or reconstitutable powder, or a liquid, i.e. a syrup or drink.

The present invention relates to a composition comprising a combination of at least one proteolytic enzyme, such as subtilisin, and at least one lipolytic enzyme, for use in preventing triglyceride synthesis, advantageously by degrading 2-monoacylglycerol in the intestine. The subject matter of the invention is also such a composition for use as a medicament, as a cosmetic agent, as a medical device, as a food composition, as a food supplement or else as a nutriceutical, in particular for use in preventing or treating obesity, atherosclerosis or type II diabetes, or else for use in preventing or reducing excess weight.